Navigation Links
Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
Date:3/31/2009

KING OF PRUSSIA, Pa., March 31 /PRNewswire/ -- Successful and seamless completion of clinical trial enrollment requires careful forecasting of screened to randomized patients, market research, an effective recruitment strategy, and project management guided by real time metrics.

MediciGlobal's President and CEO Liz Moench notes: "This is achievable when clinical trial sites are engaged and motivated to meet timelines." She adds, "We had great team chemistry with the study sponsor -- a major Pharma company -- and clinical trial sites were highly enthusiastic about the recruitment program. They were supported by a very experienced MediciGlobal team."

Restless Legs Syndrome (RLS) involves an irresistible urge to move the legs (medically known as akathisia). It is estimated that 7% to 10% of the general population is affected by RLS and 60% of cases are inherited. A serious and common side effect is sleep disturbance.

The recruitment campaign encouraged those diagnosed with RLS and sleep disturbance to seek out the clinical study. An education based approach reached undiagnosed RLS sufferers. Furthermore, MediciGlobal engaged study sites and the RLS community in the development of materials from the start. This ensured that materials were designed for maximum effectiveness.

RLS affects adults of all ages. It is twice as common in women as in men. While more prevalent in adults older than 60 years of age, about 18% of RLS patients are between the ages of 40 to 60, and 7% between 20 and 40. Every clinical study offers unique characteristics, challenges and opportunities. Since the clinical trial spanned all age groups, the recruitment campaign required a segmented approach. Each direct-response strategy used was carefully tracked for performance and cost effectiveness.

The integrated yet segmented recruitment campaign generated considerable interest, yielding nearly 55,000 web hits and click throughs to the online study screener. The project team paced advertising to each study site, in order to ensure that site staff could handle the workflow and no RLS patients were lost in the screening process.

"The team approached this project in a non traditional way," says Moench. "The sponsor was open and willing to fresh ideas and marketing techniques, and clinical trial site enthusiastically embraced them. The results speak for themselves."

This clinical study builds on a long term relationship between the study sponsor and MediciGlobal, where many recruitment programs for a range of therapeutic areas have been successfully implemented.


'/>"/>
SOURCE MediciGlobal
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Major deCODE-led Study Underscores Role of the Brain in Obesity
2. Isogen Launches Major New Facility to Address Global Biopharma Demand
3. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
4. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
5. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
6. First Ever Study on Alzheimers Disease Treatment in Hispanics Presented at Major Medical Meeting
7. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
8. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
9. Oridion Announces Major Medical Research and Congress Presentations
10. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
11. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und ... Überlegenheit in ‚ausgezeichneter plus guter ... Colons    ,      (Logo: ... gab heute neue positive Daten von der MORA-Studie ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... , May 24, 2016 Open ... in Clinical Neurophysiology  Elsevier , a ... and services, today announced the launch of ... access journal that focuses on clinical practice issues in ... reports, clinical series, normal values and didactic reviews. It ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... One Florida-based plastic surgeon’s ... according to an article published May 13th on Vanity Fair. In fact, ... having snippets of their procedures broadcast to more than 800,000 Snapchat fans. Commenting on ...
(Date:5/25/2016)... ... 25, 2016 , ... Indiana Fiber Network, LLC (IFN), the ... IFN as a fiber transport provider. IFN provided Lake City Bank with network ... , “IFN provides fiber transport to Lake City Bank, which includes ...
(Date:5/25/2016)... ... ... CloudLIMS, joins an elite number of companies that have earned a spot ... by CIOReview. , In a deliberate session with the honorary industrial experts, a list ... concluded with. The positioning is based on evaluation of CloudLIMS’ specialties in Automated Sample ...
(Date:5/25/2016)... ... May 25, 2016 , ... DKT International, one of ... world, is pleased to release their 2015 global impact data. In 2015, DKT ... 14,000 maternal deaths and 3.8 million unsafe abortions across 21 countries worldwide. ...
(Date:5/25/2016)... ... 2016 , ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, ... new wellness suites . The two 1,350 sq. ft. suites which debuted in ... and insuite amenities, from a custom soap selection and in-suite exercise kit to a ...
Breaking Medicine News(10 mins):